Caris Life Sciences Q2 FY26 net loss narrows to USD 0.6 million; revenue rises 45% to USD 263.7 million
C
CAI• Q2 results and operating metrics
- Caris Life Sciences posted Q2 2026 revenue of USD 263.7 million, up 45% year over year.
- Net loss narrowed to USD 0.6 million.
- Gross margin rose 5 percentage points to 68%.
- Adjusted EBITDA (non-GAAP) climbed to USD 55.7 million.
- Operating cash flow increased to USD 28.5 million.
- Clinical cases rose 18% to 59,200.
- The company launched Caris Detect, a multi-cancer early detection test.
- Caris raised its 2026 revenue guidance to USD 1.03 billion-USD 1.04 billion.
- CEO David Dean Halbert called it a record quarter.
TS
•
Caris Life Sciences Q2 FY26 net loss narrows to USD 0.6 million; revenue rises 45% to USD 263.7 million - CAI News | Rallies
